Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Sareum Holdings PLC (SAR.L) US Patent Notice of Allowance for SDC-1802
Cambridge, UK, 30 July 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases.
Sareum Holdings PLC (SAR.L) Covid-19 Research Project Results
Completed Covid-19 Research Project Delivers Encouraging Results
Sareum Holdings PLC (SAR.L) Subscription to raise £900,000
Subscription to raise £900,000 to progress proprietary TYK2/JAK1 programmes through final stages of preclinical development
Sareum Holdings PLC (SAR.L) Research Update
Sareum Notes SRA737 Combination Data to be Presented at the AACR Annual Meeting